Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.62 |
| ▸ | NOS2 | P35228 | 5/20 | 0.62 |
| ▸ | NOS1 | P29475 | 4/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12633376 | 0.85 | NOS2 (0.58) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL11818312 | 0.83 | NOS3 (0.61) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL11809448 | 0.81 | NOS3 (0.58) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL6560519 | 0.79 | GABRA1 (0.42) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL23836653 | 0.79 | NOS3 (0.41) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL18469882 | 0.78 | NOS3 (0.55) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL487712 | 0.78 | UHRF1 (0.46) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL91489 | 0.77 | — | — | |
| SCHEMBL13899674 | 0.77 | NOS3 (0.53) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL14510525 | 0.77 | NOS3 (0.53) | NOS3NOS2NOS1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20210363143-A1 | PYRIDO-IMIDAZO RIFAMYCINS | BIOFER S.P.A. (IT) | 2021-11-25 | — | — | US | disclosed |
| US-11028086-B2 | Pyrido-imidazo rifamycins | BIOFER S.P.A. (IT) | 2021-06-08 | — | — | US | disclosed |
| US-20200157104-A1 | PYRIDO-IMIDAZO RIFAMYCINS | BIOFER S.P.A. (IT) | 2020-05-21 | — | — | US | disclosed |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| WO-2020027304-A1 | NOVEL CAROTENOID-RELATED DERIVATIVES, AND SALTS, ESTERS, OR AMIDES THEREOF | アスタファーマシューティカルズ株式会社 | 2020-02-06 | — | — | WO | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
| WO-2019032936-A1 | LINCONSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT ADN FELLOWS OF HARVARD COLLEGE (US) | 2019-02-14 | — | — | WO | disclosed |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2006014762-A1 | SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | NOS3 3183/4885NOS2 4131/4885NOS1 3992/4885 |
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | LNPEP, LCLAT1, NPEPPS | NOS3 2958/4885NOS2 2859/4885NOS1 1833/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | NOS3 612/4885NOS2 3170/4885NOS1 3493/4885 |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | NOS3 1921/4885NOS2 2679/4885NOS1 2677/4885 |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | NOS3 4573/4885NOS2 4707/4885NOS1 4763/4885 |
| US-11028086-B2 | Pyrido-imidazo rifamycins | RIF1, IPO4, PIR | NOS3 3571/4885NOS2 3011/4885NOS1 3517/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | NOS3 3190/4885NOS2 3813/4885NOS1 4014/4885 |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | NOS3 3341/4885NOS2 4219/4885NOS1 4784/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | NOS3 2072/4885NOS2 1543/4885NOS1 2008/4885 |
| US-20210363143-A1 | PYRIDO-IMIDAZO RIFAMYCINS | RIF1, IPO4, PIR | NOS3 3571/4885NOS2 3011/4885NOS1 3517/4885 |
| US-20200157104-A1 | PYRIDO-IMIDAZO RIFAMYCINS | RIF1, IPO4, PIR | NOS3 3571/4885NOS2 3011/4885NOS1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.